{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
pyrazinoic acid
to a specific field?
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Benzoylpas (more known as calcium benzoyl-PAS) is a benzoic acid-modified form of para-aminosalicylate, used to treat pulmonary tuberculosis.
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Thenalidine is an antihistamine with anticholinergic properties used as an antipruritic drug. It was withdrawn from the US, Canadian, and UK markets due to a risk of neutropenia. Thenalidine is an antagonist of the H1-receptor.
Status:
US Previously Marketed
Source:
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE by MIKART
(1997)
Source URL:
First approved in 1956
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain. It can also be used to treat chronic pain, breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction.
Status:
US Previously Marketed
Source:
LORFAN by ROCHE
(1956)
Source URL:
First approved in 1956
Source:
LORFAN by ROCHE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Levallorphan (brand name Lorfan), is an opiate antagonist of morphine family. Levallorphan was formerly used in general anesthesia, mainly to reverse the respiratory depression produced by opioid analgesics and barbiturates used for induction of surgical anaesthesia whilst maintaining a degree of analgesia. Levallorphan was also used in combination with opioid analgesics to reduce their side effects, mainly in obstetrics. The combination of levallorphan with pethidine was used so frequently, a standardized formulation was made available, known as Pethilorfan, by Roche Products Ltd in later 1950s. Is known to be used for narcotic overdose. Levallorphan is similar to naloxone but differs from naloxone in that it also possesses some agonist properties. It acts as an antagonist and partial agonist of the mu opioid receptor (MOR). Levallorphan can produce severe mental reactions at sufficient doses including hallucinations, dissociation, and other psychotomimetic effects, dysphoria, anxiety, confusion, dizziness, disorientation, derealization, feelings of drunkenness, and bizarre, unusual, or disturbing dreams.
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Benzoylpas (more known as calcium benzoyl-PAS) is a benzoic acid-modified form of para-aminosalicylate, used to treat pulmonary tuberculosis.
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Status:
US Previously Marketed
Source:
MIOKIN by MALLINCKRODT
(1955)
Source URL:
First approved in 1955
Source:
MIOKIN by MALLINCKRODT
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Diprotrizoic acid is dipropionamino compound. It is a diagnostic aid. Diprotrizoic acid was introduced for urography but it produced more side effects than diatrizoic acid.
Status:
First approved in 1955
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
HYDROXYDIONE is a neuroactive steroid used formerly as a general anesthetic. It was discontinued due to a high incidence of post-anesthetic thrombophlebitis, delayed onset of anesthesia and an unacceptably long duration of action.
Status:
US Previously Marketed
Source:
Marsilid Phosphate by Hoffmann-La Roche
(1955)
Source URL:
First approved in 1955
Source:
Marsilid Phosphate by Hoffmann-La Roche
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.
